IP Library Granted Patent US 10,206,972
Granted Patent B2
US 10,206,972 · App. 15/301,092 · Granted Feb 19, 2019

Anti-vascular disease and antitumor pharmaceutical composition and use thereof

Inventors: Hua Wang (Guangzhou, CN); Huanchun Liang (Guangzhou, CN)
Assignees: GUANGZHOU YIDAI PHARMACEUTICAL CO., LTD.; SUN YAT-SEN UNIVERSITY
A61K38/14A61K9/0019A61K9/1658A61K9/19A61K9/5094A61K9/5153A61K9/5161A61K31/137A61K31/167A61K31/573A61K31/661A61K9/5115A61K9/5192
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,206,972
App. No.
15/301,092
Granted
Feb 19, 2019
Kind
B2
Abstract

An anti-vascular diseases and antitumor pharmaceutical composition is provided in the present invention, and it includes effective ingredients including bleomycin antitumor antibiotic, adrenal glucocorticoid, epinephrine or pharmaceutically acceptable salts thereof in a weight ratio of (1-8):(2-5):(0.00005-0.001). The pharmaceutical composition provided can be used for treatment of vascular diseases and tumors.

Claims (24)

1. An anti-vascular malformation pharmaceutical composition, wherein the pharmaceutical composition comprises effective ingredients comprising pingyangmycin, dexamethasone and epinephrine or pharmaceutically acceptable salts thereof in a weight ratio of 7:4.3755:0.00035.

2. The pharmaceutical composition according to claim 1 , wherein a total weight of the pingyangmycin, dexamethasone, and epinephrine accounts for 20%-90% of the weight of the pharmaceutical composition.

3. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable auxiliary.

4. The pharmaceutical composition according to claim 3 , wherein the pharmaceutically acceptable auxiliary comprises at least one of a pH regulator and mannitol.

5. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is in a dosage form of injection, freeze-dried powder, or microspheres.

6. The pharmaceutical composition according to claim 5 , wherein the microspheres are albumin microspheres, magnetic nano-microspheres, control-released magnetic nano-microspheres, or cellular targeted magnetic nano-microspheres.

7. A method for treating vascular malformations, comprising the step of:

preparing a medication comprising the pharmaceutical composition of claim 1 ;

administering the medication to a patient suffering from the vascular malformations.

8. The method for treating vascular malformations, comprising the step of:

preparing a medicine comprising the pharmaceutical composition of claim 2 ;

administering the medication to a patient suffering from the vascular malformations.

9. The method for treating vascular malformations, comprising the step of:

preparing a medicine comprising the pharmaceutical composition of claim 3 ;

administering the medication to a patient suffering from the vascular malformations.

10. The method for treating vascular malformations, comprising the step of:

preparing a medicine comprising the pharmaceutical composition of claim 4 ;

administering the medication to a patient suffering from the vascular malformations.

11. The method for treating vascular malformations, comprising the step of:

preparing a medicine comprising the pharmaceutical composition of claim 5 ;

administering the medication to a patient suffering from the vascular malformations.

12. The method for treating vascular malformations, comprising the step of:

preparing a medicine comprising the pharmaceutical composition of claim 6 ;

administering the medication to a patient suffering from the vascular malformations.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2016
From: WANG, HUA; LIANG, HUANCHUN
To: GUANGZHOU YIDAI PHARMACEUTICAL CO., LTD.; SUN YAT-SEN UNIVERSITY
Reel/Frame 040013/0627 →
Priority Claims (1)
CN 2014 1 0133926 · Apr 3, 2014 · national
Continuity (1)
Related Publication 20170087208A1 · Mar 30, 2017